Life Biosciences to Present Phase 1 Interim Data for ER-100 in Glaucoma
LONGEFI Signal
How this development was scored.
How authoritative and verifiable the underlying source is.
How prominent or noteworthy the development is based on its editorial classification.
How close this type of development sits to meaningful human clinical impact.
How strongly the development connects to companies and commercial or strategic context.
Measures significance, not direction or investment attractiveness.Methodology
A high LONGEFI Signal means the development is significant — not that it is positive news, a good investment, or expected to increase a company's share price.
Significance only. Direction-neutral: negative developments can score just as high. Not an investment rating, not a forecast, not a recommendation.
Event tier D · Tier ceiling 49 · LONGIFI_SIGNAL_V1
Quick take
Life Biosciences announced it will present interim clinical safety and tolerability data from its ongoing Phase 1 trial of ER-100, an epigenetic restoration candidate, in patients with glaucoma.
What happened
Life Biosciences announced an upcoming oral presentation of initial data from its ongoing Phase 1 trial evaluating ER-100 in patients with optic neuropathies.
The presentation is scheduled for October 8, 2026, during the Glaucoma Digital session at the Eyecelerator @ American Academy of Ophthalmology (AAO) 2026 conference in New Orleans, LA.
ER-100 is the lead investigational candidate from the company's Epigenetic Restoration platform, designed to reset cellular gene expression patterns and restore function in retinal ganglion cells.
The therapy uses controlled expression of three transcription factors (OCT4, SOX2, and KLF4) and is being evaluated under trial identifier NCT07290244, which initiated in the first quarter of 2026.
Why it matters
Current standard therapies for optic neuropathies such as open-angle glaucoma and non-arteritic anterior ischemic optic neuropathy focus on pressure management but do not reverse damage to retinal ganglion cells.
This presentation will deliver the first-in-human clinical data for a partial cellular reprogramming therapy, addressing critical questions regarding the safety of expressing transcription factors to restore cellular youthfulness in vivo.
Market impact
Demonstrating safety and tolerability for ER-100 in a Phase 1 setting is a key hurdle for the epigenetic rejuvenation field, which has faced questions regarding potential oncogenic risks of in vivo transcription factor expression.
A positive safety signal would support the viability of partial epigenetic reprogramming as a class, potentially lifting the valuation of early-stage peers working with similar transcription-factor platforms.
What comes next
The presentation of interim Phase 1 data by Chief Scientific Officer Sharon Rosenzweig-Lipson, PhD, on October 8, 2026.
Subsequent trial readouts evaluating safety, tolerability, and visual function endpoints in the patient cohort.
Company relevance
Structured relationships recorded at publication time. Sector exposure is thematic only — it does not mean the company took part. Not market data.
- Life Biosciences
Company development · CLINICAL · TECHNOLOGY
Life Biosciences is the sponsor of the clinical trial and the developer of the ER-100 candidate being evaluated.
Sources
- Life Biosciences Inc.LIFE_BIOSCIENCES:COMPANY_NEWS